These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 18075294)
1. Somatostatin receptor scintigraphy in thoracic diseases. Ameri P; Gatto F; Arvigo M; Villa G; Resmini E; Minuto F; Murialdo G; Ferone D J Endocrinol Invest; 2007 Nov; 30(10):889-902. PubMed ID: 18075294 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161 [TBL] [Abstract][Full Text] [Related]
3. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Oberg K; Eriksson B Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700 [TBL] [Abstract][Full Text] [Related]
5. [The scintigraphy of somatostatin receptors in the carcinoid tumor]. Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324 [TBL] [Abstract][Full Text] [Related]
6. Peptide receptor imaging and therapy. Kwekkeboom D; Krenning EP; de Jong M J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002 [TBL] [Abstract][Full Text] [Related]
7. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Chua S; Gnanasegaran G; Cook GJ Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221 [TBL] [Abstract][Full Text] [Related]
8. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related]
9. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings. Kuyumcu S; Adalet I; Sanli Y; Turkmen C; Ozkan ZG; Yilmazbayhan D Ann Nucl Med; 2012 Nov; 26(9):689-97. PubMed ID: 22802007 [TBL] [Abstract][Full Text] [Related]
12. Initial staging of lymphoma with octreotide and other receptor imaging agents. Ferone D; Semino C; Boschetti M; Cascini GL; Minuto F; Lastoria S Semin Nucl Med; 2005 Jul; 35(3):176-85. PubMed ID: 16098291 [TBL] [Abstract][Full Text] [Related]
13. A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions. Minutoli F; Herberg A; Sindoni A; Cardile D; Cucinotta M; Baldari S J Endocrinol Invest; 2012 Jul; 35(7):708-9. PubMed ID: 22932274 [No Abstract] [Full Text] [Related]
14. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT. Madrzak D; Mikołajczak R; Kamiński G Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886 [TBL] [Abstract][Full Text] [Related]